Annual Cash & Cash Equivalents
$23.00 M
-$4.87 M-17.47%
March 1, 2024
Summary
- As of February 8, 2025, GRCE annual cash & cash equivalents is $23.00 million, with the most recent change of -$4.87 million (-17.47%) on March 1, 2024.
- During the last 3 years, GRCE annual cash & cash equivalents has fallen by -$27.94 million (-54.84%).
- GRCE annual cash & cash equivalents is now -54.84% below its all-time high of $50.94 million, reached on March 1, 2021.
Performance
GRCE Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$15.15 M
-$4.24 M-21.86%
September 1, 2024
Summary
- As of February 8, 2025, GRCE quarterly cash and cash equivalents is $15.15 million, with the most recent change of -$4.24 million (-21.86%) on September 1, 2024.
- Over the past year, GRCE quarterly cash and cash equivalents has dropped by -$3.39 million (-18.28%).
- GRCE quarterly cash and cash equivalents is now -70.25% below its all-time high of $50.94 million, reached on March 1, 2021.
Performance
GRCE Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
GRCE Cash And Cash Equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -17.5% | -18.3% |
| 3 y3 years | -54.8% | -56.6% |
| 5 y5 years | +36.4% | -22.3% |
GRCE Cash And Cash Equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -54.8% | at low | -60.5% | at low |
| 5 y | 5-year | -54.8% | +61.5% | -70.3% | +31.2% |
| alltime | all time | -54.8% | +6883.9% | -70.3% | -100.0% |
Grace Therapeutics Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $15.15 M(-21.9%) |
| Jun 2024 | - | $19.39 M(-15.7%) |
| Mar 2024 | $23.00 M(-17.5%) | $23.00 M(+24.0%) |
| Dec 2023 | - | $18.55 M(-31.3%) |
| Sep 2023 | - | $26.99 M(+24.8%) |
| Jun 2023 | - | $21.63 M(-22.4%) |
| Mar 2023 | $27.88 M(-8.1%) | $27.88 M(+6.2%) |
| Dec 2022 | - | $26.24 M(-24.9%) |
| Sep 2022 | - | $34.93 M(-9.0%) |
| Jun 2022 | - | $38.38 M(+26.5%) |
| Mar 2022 | $30.34 M(-40.4%) | $30.34 M(-8.1%) |
| Dec 2021 | - | $33.01 M(-10.6%) |
| Sep 2021 | - | $36.93 M(-9.9%) |
| Jun 2021 | - | $40.98 M(-19.6%) |
| Mar 2021 | $50.94 M(+257.7%) | $50.94 M(+91.9%) |
| Dec 2020 | - | $26.55 M(+129.8%) |
| Sep 2020 | - | $11.55 M(-4.7%) |
| Jun 2020 | - | $12.12 M(-14.9%) |
| Mar 2020 | $14.24 M(-15.6%) | $14.24 M(-27.6%) |
| Dec 2019 | - | $19.66 M(+0.8%) |
| Sep 2019 | - | $19.50 M(+22.4%) |
| Jun 2019 | - | $15.94 M(-5.5%) |
| Mar 2019 | $16.87 M(+165.0%) | $16.87 M(-20.5%) |
| Dec 2018 | - | $21.21 M(+359.2%) |
| Sep 2018 | - | $4.62 M(-52.8%) |
| Jun 2018 | - | $9.78 M(+53.6%) |
| Mar 2018 | $6.37 M(-13.1%) | $6.37 M(-35.8%) |
| Dec 2017 | - | $9.92 M(+130.9%) |
| Sep 2017 | - | $4.30 M(-26.2%) |
| Jun 2017 | - | $5.82 M |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2017 | $7.33 M(+228.0%) | - |
| Nov 2016 | - | $1.35 M(-38.9%) |
| Aug 2016 | - | $2.21 M(+107.2%) |
| May 2016 | - | $1.07 M(-52.3%) |
| Feb 2016 | $2.23 M(+113.3%) | $2.23 M(-37.1%) |
| Nov 2015 | - | $3.55 M(+80.4%) |
| Aug 2015 | - | $1.97 M(+99.6%) |
| May 2015 | - | $985.50 K(-5.9%) |
| Feb 2015 | $1.05 M(+72.5%) | $1.05 M(-34.4%) |
| Nov 2014 | - | $1.60 M(>+9900.0%) |
| Aug 2014 | - | $0.00(-100.0%) |
| May 2014 | - | $194.70 K(-67.9%) |
| Feb 2014 | $607.10 K(-48.1%) | $607.10 K(-77.2%) |
| Nov 2013 | - | $2.67 M(+133.1%) |
| Aug 2013 | - | $1.14 M(+37.9%) |
| May 2013 | - | $829.50 K(-29.0%) |
| Feb 2013 | $1.17 M(-26.9%) | $1.17 M(+52.3%) |
| Nov 2012 | - | $767.30 K(-30.3%) |
| Aug 2012 | - | $1.10 M(-7.2%) |
| May 2012 | - | $1.19 M(-25.8%) |
| Feb 2012 | $1.60 M(+385.4%) | $1.60 M(+1159.1%) |
| Nov 2011 | - | $127.00 K(-60.9%) |
| Aug 2011 | - | $324.50 K(-22.0%) |
| May 2011 | - | $416.10 K(+26.3%) |
| Feb 2011 | $329.40 K(-18.7%) | $329.40 K(-83.6%) |
| Nov 2010 | - | $2.01 M(>+9900.0%) |
| Aug 2010 | - | $7200.00(-97.2%) |
| May 2010 | - | $259.00 K(-36.0%) |
| Feb 2010 | $405.00 K | $405.00 K(+273.6%) |
| Nov 2009 | - | $108.40 K |
FAQ
- What is Grace Therapeutics annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Grace Therapeutics?
- What is Grace Therapeutics annual cash & cash equivalents year-on-year change?
- What is Grace Therapeutics quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Grace Therapeutics?
- What is Grace Therapeutics quarterly cash and cash equivalents year-on-year change?
What is Grace Therapeutics annual cash & cash equivalents?
The current annual cash & cash equivalents of GRCE is $23.00 M
What is the all time high annual cash & cash equivalents for Grace Therapeutics?
Grace Therapeutics all-time high annual cash & cash equivalents is $50.94 M
What is Grace Therapeutics annual cash & cash equivalents year-on-year change?
Over the past year, GRCE annual cash & cash equivalents has changed by -$4.87 M (-17.47%)
What is Grace Therapeutics quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of GRCE is $15.15 M
What is the all time high quarterly cash and cash equivalents for Grace Therapeutics?
Grace Therapeutics all-time high quarterly cash and cash equivalents is $50.94 M
What is Grace Therapeutics quarterly cash and cash equivalents year-on-year change?
Over the past year, GRCE quarterly cash and cash equivalents has changed by -$3.39 M (-18.28%)